Comparison

Goat anti Synphilin-1 (C-term)

Item no. 18-511-244180
Manufacturer GENWAY
Amount 0,2 ml
Category
Type Antibody
Specific against other
Host Goat
ECLASS 10.1 32160702
ECLASS 11.0 32160702
UNSPSC 12352203
Alias GWB-53511C
Similar products 18-511-244180
Available
Genway ID:
GWB-53511C
Host Animal:
Goat
Immunogen:
Synthetic Peptide: 829SLELNGEKDKDKGRTLQRT847
Specificity:
Synphilin-1 C-terminal
Specificity:
Amino acid sequence 829-847 of human synphilin-1 protein.
Type of Product:
Polyclonal Antibodies for Neuroscience
Concentration:
Not determinedPreservatives: NaN3
Buffer:
Not determinedApplications Notes : ELISA using immunizing peptide (1:10 655). IHC using formalin-fixed paraffin-embedded sections (1:400). Western blot (1:1000). Suitability for use in IHC using paraformaldehyde-fixed frozen sections has not been determined but use in such assays should not necessarily be excluded.
Warning:
This product contains sodium azide which has been classified as Xn (Harmful) in European Directive 67/548/EEC in the concentration range of 0. 1â ??1. 0%. When disposing of this reagent through lead or copper plumbing flush with copious volumes of water to prevent azide build-up in drains. Goat anti-Synphilin-1 (C-term). Goat Antibody to Synphilin-1 C-terminal
Subunit:
Associates with SNCA RNF19A AND PARK2.
Tissue Specificity:
Widely expressed with highest levels in brain heart and placenta.
Ptm:
Ubiquitinated; mediated by SIAH1 or RNF19A and leading to its subsequent proteasomal degradation.
Disease:
Defects in SNCAIP are a cause of Parkinson disease (PD) [MIM:168600]. PD is a complex multifactorial disorder that typically manifests after the age of 50 years although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia resting tremor muscular rigidity and postural instability as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins) in surviving neurons in various areas of the brain.
Miscellaneous:
Constructs encoding portions of SNCA and SNCAIP co-transfected in mammalian cells promote cytosolic inclusions resembling the Lewy bodies of Parkinson disease. Coexpression of SNCA SNCAIP and PARK2 result in the formation of Lewy body-like ubiquitin-positive cytosolic inclusions. Familial mutations in PARK2 disrupt the ubiquitination of SNCAIP and the formation of the ubiquitin-positive inclusions. These results provide a molecular basis for the ubiquitination of Lewy body-associated proteins and link PARK2 and SNCA in a common pathogenic mechanism through their interaction with SNCAIP.
Similarity:
Contains 6 ANK repeats.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 0,2 ml
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close